Trial
NCT03843125
A Study of Baricitinib in Participants With Systemic Lupus Erythematosus (SLE)
Phase IIITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Eli Lilly and Company
Collaborators
Incyte Corporation
Condition
Systemic Lupus Erythematosus
Intervention
Baricitinib
Why stopped
Study terminated due to insufficient evidence to support a positive benefit: risk profile. Safety findings were consistent with previously published OLUMIANT data
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2023-05-16